DocGo Inc. (DCGO) Earnings Call Transcript & Summary
May 8, 2023
Earnings Call Speaker Segments
Mike Cole
executiveThank you, operator. Prior to handing things off to management, I'd like to offer a few comments about forward-looking statements. Everything said on this conference call that isn't a historical fact counts as a forward-looking statement. Terms such as anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, along with other comparable expressions, are typically how such forward-looking statements get identified. Such forward-looking statements don't amount to guarantees regarding future performance and could involve, and are subject to, particular risks and uncertainties plus other factors that might impact DocGo's business, financial condition and other operating results; among these are, without limitation, the risk factors and other qualifications found in DocGo's annual report on Form 10-K, quarterly reports filed on Form 10-Q, and other reports and statements DocGo has filed with the SEC, to which your attention is directed. Actual outcomes and results could differ materially from what these forward-looking statements express or imply; furthermore, references to non-GAAP financial measures appear in today's call. Reconciliations of these non-GAAP financial measures against the most directly comparable GAAP financial measures appear directly as part of this call or are included in our earnings, which is posted on our website, docgo.com, as well as in our filings with the Securities and Exchange Commission. What's contained in this call is accurate only as of the date discussed. Investors shouldn't assume that statements will stay relevant and operative at a later time. We assume no obligation to update any information discussed in this call in the future. At this time, it is now my pleasure to turn the call over to Mr. Anthony Capone, CEO of DocGo. Anthony, please go ahead.
Anthony Capone
executiveThank you, Mike, and I appreciate everyone being here with us today. Our first quarter was incredibly active, since we rolled out several new initiatives toward the end of that period, which involved tough logistical deadlines. Those launches, I'm happy to say, have performed very well, and our ramp-up is either on target or running ahead of it. There has never been stronger demand for DocGo services, largely because the requirement for population health offerings is growing quickly throughout the United States. In Q1, our revenue reached $113 million, which is down 4% compared with the same period last year. But when mass COVID testing is factored out of the comparison, our revenues rose 40% versus a year earlier. A strong base has been established for what lies ahead, and we anticipate that the recent project launches will produce meaningful quarter-over-quarter improvements in revenue as well as adjusted EBITDA over the next several quarters. Now that the first quarter is behind us, we are reaffirming our guidance for 2023: revenue between $500 million and $510 million, and adjusted EBITDA between $45 million and $50 million. Right now, I'll pass things along to Lee Bienstock, our President and COO, who will discuss a few of our operational highlights from the quarter. Lee, the floor is yours.
Lee Bienstock
executiveThanks, Anthony. We're still seeing a lot of growth when it comes to new contract RFP opportunities, in both mobile health and medical transportation. Since we last reported on March 13, 2023, the count of open RFPs has doubled, and together they represent a total contract value of roughly $1.5 billion. That rise in RFPs comes from more opportunities in geographies where we already operate as well as new ones, plus our stronger internal review and submission capabilities. Specifically, new RFP activity for mobile health services remains substantial. DocGo has made a successful transition away from a business centered on mass COVID testing toward a mobile health business that covers a broad range of clinical services. Right now, our backlog — meaning contracts we've been awarded that haven't been fully deployed yet — sits at about $205 million. Back on March 13 of this year, the figure we shared was $180 million. What's driving the recent bump is mainly a multiyear mobile health contract with a municipality, plus a handful of smaller deals. Then in April, we told everyone about teaming up with Fresenius Medical Corporation — they're the biggest kidney dialysis provider in the U.S. — to deliver remote patient monitoring, chronic care management, and mobile urgent care. Between Fresenius and the nephrology practices tied to it, there's a huge patient base of 300,000. Enrollment should kick off in May, and we anticipate several markets scaling up aggressively during Q3. Because these revenue sources come in on a recurring basis and because patients dealing with chronic kidney disease can benefit from these services so broadly, this opportunity has us genuinely enthusiastic. Working from the 8 CPT codes in place today, we figure the per-patient, per-month revenue potential lands at roughly $250 — with $100 of that coming from RPM and the other 150 from CCM. Beyond that, it turns into a self-referring mechanism any time a monitored patient shows abnormal vitals or is rapidly decompensating. Where it makes sense to do so, DocGo will send a mobile health care provider to respond in person. Once this RPM and CCM service is completely up and running, we expect its gross margins to exceed 50%, and it should come with fairly modest SG&A expenses, a very low cost to bring in customers, and strong lifetime value per customer. In the months ahead, we'll collaborate closely with Fresenius and the nephrology practices tied to it in order to pinpoint and sign up suitable patient groups for the RPM and CCM program at DocGo. We expect money brought in from RPM and CCM to play a major part in driving revenue growth for 2024, though the first effects should show up late in 2023. Also during the quarter, we bought CRMS, which refers to cardiac remote monitoring solutions. Cardiology is among the fastest-expanding areas within RPM, and that opens up roughly 400,000 patients for us to bring into RPM and CCM programs. Before this, CRMS only addressed the CIED space—meaning cardiac implanted electronic devices. Today, as part of DocGo, we're able to extend CCM offerings to those same individuals too. That's a clear example of how DocGo's licenses, technology, and mobile health team can improve outcomes for patients and cut costs for payers, while also expanding the revenue we generate through remote patient monitoring. Our RPM/CCM approach is deliberately centered on cardiology through CRMs and nephrology through Fresenius, and soon we plan to reveal strategic partners in endocrinology as well as pulmonology. Using organic as well as inorganic routes, we aim to serve more than 50,000 patients with RPM and CCM offerings by the close of 2023. Since chronic care management is the subject here, it’s essential to grasp the strategic link connecting our municipal population health programs with our CCM programs. Over the past 12 months, 75% of the patients we saw through only 2 programs—roughly 600,000 patients—either lacked a primary care provider or were unsure who that provider was. Many of these individuals require someone to oversee their care, and that’s the role DocGo fills, handling care for America’s underserved populations. I’ll now hand things back to Anthony.
Anthony Capone
executiveAppreciate that, Lee. Prior to passing things along to Norm, I'd like to discuss margins along with our rapid normalization initiative. During January and February, one of our major customers requested that we speed up deployment of a sizable project because the incumbent was winding down more quickly than the contract required. We managed to get this launched successfully on that faster timeline, and that's what pushed us past our revenue targets, though it came with the cost of margins that were significantly compressed. That said, once March arrived and after the quarter closed, we saw a substantial recovery once those costs eased. Things look excellent for us right now, and what we anticipate for margins across the year hasn't changed. What happened was simply that January and February brought a steeper drop than we'd initially anticipated because of that faster rollout. On the bright side, the recovery also came in stronger than we'd projected, and margins are moving in a favorable direction. Turning to our rapid normalization initiative, it currently ranks among our top priorities. We're still in the early stages of this effort, but as I noted earlier, during March and after the quarter ended, we achieved meaningful improvements in cost reduction throughout the company, and we anticipate these will bolster margins in Q2 and continue for the rest of the year. One major piece of this work involves reducing the effect of staffing agency labor. Over just the past 60 days, our utilization rate for agency labor has fallen from 52% down to 41%, and we anticipate further gains in the months ahead. We've additionally recorded a 40% reduction in the count of rental vehicles in use as we swap them for owned or leased units, which run at roughly half the expense. Finally, the extraordinarily elevated overtime rate in mobile health that we dealt with during the fourth quarter and the start of the first quarter is now easing as we put controls in place, and those controls should move that figure toward a long-term target of 5% overtime usage, down from the recent peak of 17%. At present, overtime sits at roughly 7%. Beyond our rapid normalization initiative, we're also observing a loosening macro labor market, which supports our growth and margin goals too. Taken together, we anticipate these steps will back our projected 37% gross margin exit rate for 2023. Now I'll pass things to Norm Rosenberg, our CFO, for a look at the financials.
Norman Rosenberg
executiveThanks, Anthony, and good afternoon, everyone. For Q1 2023, total revenue came in at $113 million, versus $117.9 million during the same quarter in 2022. If you strip out mass COVID testing revenue from both periods, recurring revenue grew 40% compared to a year earlier. In last year's first quarter, mass cover testing contributed an estimated $38 million, whereas testing revenue in this year's first quarter was roughly $1 million — under 1% of total revenue for that period. Mobile Health revenue in Q1 2023 reached $72.9 million, down from $90.1 million in Q1 2022. Again, if we set aside the estimated mass COVID testing revenue in each period, Mobile Health revenue rose 38%. Medical Transportation revenue climbed substantially, hitting $40.1 million in Q1 2023 — a 44% jump from $27.8 million in Q1 2022. Almost every core transportation market saw revenue growth both year over year and sequentially, extending the strong momentum carried over from the second half of last year. We posted a net loss of $3.9 million in Q1 2023, versus net income of $9.4 million in Q1 2022. That net loss stemmed partly from a big jump in noncash stock compensation, which ran roughly $7 million above the prior year period and exceeded the full-year 2022 total, plus an increase of over $1 million in our insurance loss reserves and about $400,000 in nonrecurring legal costs tied to leaving the California transportation market, which we covered in our prior earnings release. Adjusted EBITDA in Q1 2023 was positive at $5.6 million, compared with $13.6 million in Q1 of '22. As always, a reconciliation from net income to adjusted EBITDA appears as a table in the earnings release. Total gross margin percentage in Q1 2023 was 28.1%, versus 33.9% in the same period of 2022, as stronger transportation segment gross margins were offset by temporary softness in Mobile Health gross margins. In Q1 2023, gross margins for the Mobile Health segment came to 27.7%, compared with 37.3% in Q1 2022. Margins were held back by continuing start-up costs for projects launched late in 2022 and early in 2023, as we mentioned on our last earnings call, and those margin-dampening effects continued to weigh on January and February. At the same time, last year's first quarter Mobile Health gross margins benefited from the COVID testing surge we saw during the opening weeks of the year. Mobile Health gross margins in March recovered nicely, helped in part by the rapid normalization project. As Anthony just noted, the key performance indicators we monitor daily are all trending positively over the last 60 days, which serves as a leading indicator for the gross margin improvement we expect in the second quarter. For the Transportation division, gross margin came in at 28.9% during Q1 2023, which was up from 22.7% in the same period of 2022. Margins for this segment keep getting better, helped along by stronger pricing on trips, our continuing move toward the higher-margin leasing business, and some relief on fuel costs. When we look forward to how gross margin will trend, we've kept building on the momentum from March, with metrics improving through April and on into May. That trajectory definitely gives us more confidence that sequential gross margin gains are achievable across the year; on top of that, we're still making headway integrating the 6 acquisitions completed since mid-2022. As that work continues, we anticipate capturing the margin gains we set as targets for each one of those entities. Now turning to operating costs. Operating expenses represented 34% of total revenues in the first quarter of 2023, versus 25% in the first quarter of 2022. The main reasons SG&A rose were depreciation and amortization along with stock compensation expense, both of which are noncash items. Noncash stock compensation expense, which gets added back when we calculate adjusted EBITDA, came to roughly $8.5 million in this year's first quarter, compared with $1.4 million in the first quarter of 2022. Looking ahead, we anticipate quarterly stock compensation expense will be much closer to the levels seen in earlier quarters, and we would expect overall operating expenses as a percentage of revenue to sit below 30% going forward. If we back out depreciation of $3.6 million plus the stock compensation expense just mentioned, SG&A equaled 24% of total revenues in the first quarter of 2023, slightly above the 22% of total revenues on that same basis in last year's first quarter. Through the rest of 2023, we would anticipate SG&A expenses falling as a percentage of revenues as sequential revenue growth comes through, while we hold the line on or, in certain cases, reduce our SG&A expenses in absolute dollar terms. Moving on now to the balance sheet. At March 31, 2023, total cash and cash equivalents, including restricted cash, stood at $127.5 million, compared with $164.1 million at the close of 2022. The decline in cash across the first quarter stemmed almost entirely from working capital factors, since accounts receivable grew by $24.7 million owing to several factors, among them the timing of payments from high credit quality customers. There were additionally approximately $11.5 million in acquisition-related payments and about $2 million in capital expenditures. Now looking at cash flow from operations. Our negative operating cash flow of $23 million for the quarter resulted entirely from changes in operating assets and liabilities, otherwise known as the working capital categories, mostly driven by a longer payment cycle from some of our larger municipal customers. This is purely a timing matter, and these rank among our highest quality receivables. We'd happily accept extended payment timelines in exchange for stronger certainty that we get paid the full amount, just as we've done with these clients so far. Next, we see this turning into a genuine edge over rivals when we submit bids for these big reducible contracts. In contrast to a lot of the vendors we're up against for such contracts, our balance sheet and capital base allow us to take on large-scale projects that demand substantial upfront spending before any service payments come in. Our liquidity lets us absorb a temporarily negative cash cycle on such projects; in fact, during the latter part of April and on into May, we saw sizable collections and cash inflows as our biggest aged invoices got settled. Even more heartening, those latest collections consisted mainly of our oldest receivables, and that should produce an improved day sales outstanding, or DSO, for our AR portfolio by the close of the second quarter. Although this pattern creates sizable swings in our cash balances between quarters, our balance sheet stays solid across the whole cash cycle. Based on the collections observed across roughly the last 20 days, we anticipate going back to producing positive operating cash flow during the second quarter, as we did every quarter from our IPO through the first quarter of 2023. Along with our $90 million line of credit, which might be increased by another $50 million, we possess the financial wherewithal to carry out stock buybacks, acquisitions, and investment in new business lines and projects with no requirement to raise fresh capital. Now for guidance. We reaffirm our revenue guidance for the year, between $500 million and $510 million. We take encouragement from the first quarter's revenue result, which came in a bit above our internal forecast, and from our backlog rising to $205 million from $180 million within only the last 7 weeks. That guided revenue range would amount to roughly 14% to 16% year-over-year top line growth on a gross reported basis, yet once you exclude the effect of mass coven testing, the revenue growth rate actually sits in the 36% to 40% annual range. We still anticipate adjusted EBITDA landing between $45 million and $50 million, with EBITDA margin acceleration anticipated as the year progresses. That wraps up my comments. Now I'd like to turn it back over to Anthony.
Anthony Capone
executiveAppreciate that, Norm. Prior to moving on to questions, I wanted to take a quick moment to remind everyone that our Investor Day is scheduled for June 20, and it's going to be held at the NASDAQ market site in New York. If you're interested in attending, please take a look at our recent press release about this event and use the registration link; at this point, operator, go ahead and open the lines for Q&A.
Michael Latimore
analystThanks. It's quite notable that the RFP value has gone up twofold from March 13, which is a pretty big jump. Could you give us a bit more detail on that? Do a few federal deals make up part of it? Or is it mainly municipalities? A little extra context there would be helpful.
Lee Bienstock
executiveAbsolutely. Mike, this is Lee. The count of RFP submissions still pending has in fact grown by two times since the last time we shared that figure. Total contract value has risen, moving from $1.1 billion up to $1.5 billion. To make that clear, what we're observing is growth pretty much everywhere, spanning federal deals all the way to local municipal deals; we keep assessing RFP possibilities throughout the range on the government side. So in essence, it has encompassed representation from federal opportunities along with local and state municipal opportunities.
Anthony Capone
executiveLet me jump in and build on what was just mentioned. Without a doubt, there's a nationwide macro trend: an increasing number of mobile health contracts, and RFPs that keep getting posted. RFIs and RFQs are basically the same thing, yet the demand keeps expanding much more for population health, particularly among underserved communities — and not only underserved communities in the more traditional sense, such as a local homeless population, but also VA, in health service, perhaps even those communities that once aren't as a parent; there's a rising need for those.
Michael Latimore
analystRight. Mobile transport turned in another strong performance this quarter. So is the revenue we're seeing in mobile transport now a solid baseline to grow from? Or did something extra help drive those gains?
Norman Rosenberg
executiveYeah, a few points. One thing we flagged when the quarter started is that a share of our ambulance contracts — I believe it was nearer to 40% at the start of the year — operated on a fee-for-service model, meaning we carried demand risk. And we've done quite well at shifting a growing portion of transport revenue toward, at minimum, our structure that includes downside margin protection. That accounts for a meaningful chunk of it, along with our effort to hold SG&A in the transport segment largely steady. That way it gets spread across a bigger revenue base. Lee, anything you'd like to add there?
Lee Bienstock
executiveMy response would mirror that. As we've noted, this has consistently represented somewhat of a blend between growth that's organic and growth that isn't, yet in truth, what we're seeing is simply an ongoing extension of a pattern that's been evident since the start of 2022. A significant portion comes down to somewhat greater concentration, additional clients beginning to engage, and I'd characterize it as a fairly solid foundation from which to grow. There's not a great deal of a nonrecurring nature in the...
Michael Latimore
analystOkay. That’s great. And then finally, regarding the target of reaching 50,000 patients in RPM—just doing a rough estimate, that would imply it’s likely a business well beyond $100 million if you get there? So first, is that accurate? And second, if you do reach 50,000, how do you view organic versus inorganic?
Anthony Capone
executiveYes. I’d say it’s truly all of the remote patient and remote device monitoring, which then leads into chronic care management, and that comes from—we’re planning on it coming from two main areas. Most of it will come from patients within the cardiology practices that are already customers of Sierra Mass, a company we mentioned we acquired very late at the end of Q1; so they essentially already provide what’s called CID, which is implantable devices; and we will be able to offer those cardiology practices RPM, which is a kind of non-implantable device. And then for the existing ones, both on CID and RPM, being able to provide them chronic care management solutions, which is actually a larger reimbursement than both of those. So that’s it. And then a smaller but still meaningful portion will come from the deal with Fresenius that we announced. So those are kind of our main focus—cardiology—and then a secondary focus is nephrology.
Matt Shea
analystMatthew Shea here, filling in for Ryan. I'd like to build on what was said about RPM. Considering that target of 50,000 patients and the 2 partners you've made public — or I guess the 1 you bought in the — the 1 you've made public with Fresenius — what percentage of the population do those 50,000 patients amount to? And if this is only a small slice of the population right now, how do you view that opportunity at present compared with how you could grow it to capture a larger share of that population? For instance, what does that overall population, and what do those partners, look like in your thinking?
Anthony Capone
executiveFor us, it's really a matter of — if you consider a provider such as the cardiologist and the nephrologist, what share of the patients they treat actually have a medical need for these services. So at a cardiology practice typically, somewhere between 30% and 50% of the patients coming to a cardiology practice will get value and satisfy the medical necessity for an RPM solution. Then beyond that, with chronic care management or PCM, both of them, roughly half of those will meet the necessity for the management services. It sort of escalates through levels of complexity. On the nephrology side, almost every patient. It's extremely close to 100% of patients who have a medical need satisfying medical necessity for RPM, and the large majority for CCM, since someone in a nephrology practice, or patients undergoing dialysis, typically doesn't only have kidney disease; they also have diabetes, hypertension. That makes them polychronic, and because of that, management becomes truly essential; that's the reason nephrology practices show such a high percentage of patients there. So when we examine it and you want to understand what the addressable market is, you can check the stats on patients with cardiovascular issues as well as patients with kidney issues, and roughly the conversion percentages I provided are what we observe for each one of those kinds of clinics and providers.
Matt Shea
analystUnderstood, that's useful. Next, if we consider expanding that RPM offering into additional specialty fields where you don't currently operate — you brought up endocrinology and pulmonology. Would you view that as growth from within, or is it more likely you'd have to team up with someone or buy a company in that area? Alternatively, what's your thinking on bringing more specialties into the RPM lineup?
Anthony Capone
executiveRight. My view is that those 2 will arrive via partnerships. There are a few exciting collaborations we'll be sharing soon. Broadly speaking, though, DocGo's approach to growing involves — we aim to locate synergies alongside other businesses, which lets us remove the cost of acquiring customers; so we'll secure a partner. Here, we've already got the 2 partners. Those partners already reach patients dealing with these conditions or several conditions, and right now they don't provide RPM, PCM or CCM or mobile urgent care to that group. So we say, fine, you already have a connection with the patient, an extremely close and personal connection with them. Can we start delivering these higher value-add services to them? So those 2 will both be introduced alongside 2 existing large players.
John Pinney
analystThis is John Pinney, sitting in for Richard. So you're adding — that backlog, you brought in $25 million roughly from the prior quarter. And does any portion of that, like, already sit inside guidance right now? Or does that lean more toward a 2024 starting story?
Anthony Capone
executiveYes. That's a good question. Lee, why don't you handle that one?
Lee Bienstock
executiveYeah, definitely, John. The bulk of those initiatives are set to kick off later in the year, and we'll scale them up considerably as we move toward 2024. So a portion of that income will begin flowing, though most of it will get underway and build throughout 2023 as we approach 2024.
Anthony Capone
executiveIt's also worth pointing out that those revenue streams tend to follow a comparable schedule; so the bulk of the revenue we've got is, well, it's a 3 — what you're essentially looking at is that $200-plus million spread across a 3-year period.
Norman Rosenberg
executiveSo the quick response there is that this isn't included in the guidance, correct? All right, that's great. And also, is there anything you can tell us about that backlog — anything at all — regarding how it would split between mobile health and transportation revenue?
Lee Bienstock
executiveCorrect. So when it comes to the growth in backlog, Mobile Health is responsible for the overwhelming share — those are freshly signed Mobile Health contracts. Essentially the entire uptick you pointed to comes from our Mobile Health agreements.
John Pinney
analystAlright, thanks. And I’ve got just one more thing to ask. Regarding the rapid normalization, you mention that Phase I is reaching completion around the end of July. That’s what the press release says, and it kind of suggests there’s a Phase II. Can you share any specifics on that? Is there going to be something extra added to that initiative after July?
Anthony Capone
executiveYes, there will be. Phase II is going to capture the additional 300 basis points. I’ll provide more specifics about exactly how that gets done. We’ve already got it fairly well mapped out. But yes, a Phase II will exist to secure the full 600 basis point margin that we, to some extent, would be giving up; and as it stands, we’re actually ahead of schedule on Phase I at this point.
Craig Jones
analystCraig, on the question about margins: first, regarding how the expansion unfolds across the year, will it come in a fairly straight line?
Norman Rosenberg
executiveNorman here. When we initially put the plan together and began discussing it, we certainly built the model in a pretty linear way. That isn't how things are actually unfolding, though, is it? My sense is the sharper portion of the curve will arrive in the sooner stages, starting now. We mentioned seeing a solid bounce back in March. Heading into Q2, we observed fairly striking movement in several of those KPIs that serve as leading indicators for us on margin. So when it comes to the margin expansion tied to fast normalization, I'd say at this point it has turned somewhat more front-end loaded across the coming couple of quarters rather than weighted toward the back. That curve is somewhat steeper, and that's a positive when the topic is margin improvement. At the same time, it's truly linear only in this sense: if we examined daily margin from now through year-end, it won't move in just one direction, correct? It will swing around somewhat depending on various developments and a great many different factors. That's the reason that although we review this data daily, we do — at times we have to step back for a broader view and extend the lens to a week, a month, or a quarter. On a quarterly basis, though, the direction should be linearly rising.
Craig Jones
analystAll right, understood. Then — it appears that with mass COVID testing revenue declining, margins have simultaneously decreased. Can we somehow quantify what the margin headwind amounted to when that revenue dropped off?
Norman Rosenberg
executiveWe've discussed this somewhat previously. It's somewhat complicated, since whenever we examine projects individually or by project category, the Mobile Health projects we're currently doing have essentially the identical margin profile — though split across various components — yet they possess the same sort of margin profile as those projects from 1 year ago or longer. The place where the effect shows up, I believe, is during those surges in mass COVID testing. That occurred in Q4 of 2021. We also saw it at the start of Q1 of 2022, when you had a project where payment is mainly based on an hourly wage — you're compensated per hour for the employees you assign to the project, whether in vehicles or anything else. And when a location that previously conducted 100 COVID tests in a day suddenly conducts 300 or 400 COVID tests daily, that additional portion carries an extremely high margin. So it was a tough comparison for us in Q4 and once more here in Q1. Broadly speaking, though, that isn't — it isn't always true. What I mean is we haven't — as we substitute margin — pardon me, as we substitute our COVID revenue over the long term, that revenue ought to arrive at roughly the same margin we'd witnessed previously.
Anthony Capone
executiveThat's right. As we submit proposals for those fresh RFPs—which are part of that very same backlog—the margin structure we built into those new agreements has essentially stayed the same.
Sarah James
analystI'd like to dig into the remarks regarding start-up costs a bit, since those weighed on gross margin. Can you tell us whether that was the big New York contractor? And should we treat it as a sort of second round of start-up costs to factor into our models for the rest of this year?
Anthony Capone
executiveYeah, given the somewhat contentious nature of the relationship with the incumbent, we're not able to reveal the specific contracting matter. But regarding your broader question, yes, it was — to a certain extent it was anticipated, since the launch time line was accelerated. So beyond the typical start-up costs, which we generally budget for, and we've mentioned that 600 basis points. Here, we needed to speed things up many months sooner than we had planned simply because the incumbent on that contract chose to essentially withdraw and sort of sidestep certain contractual obligations. And naturally, since we're a customer-first company, we came in and exceeded what the customer expected, which is why you're seeing that our revenue actually and to surpass some of our expectations, though it did arrive alongside margin contraction.
Sarah James
analystOkay, then. As you shift into the RPM area, could you explain the way that might affect your efficiency or how many patients you can treat daily, given that there will likely be extra interaction or maybe visits that take more time within the home?
Anthony Capone
executiveWe have not truly seen that those visits will take more time. Even so, we plan, during our Investor Day in June, to give some highly specific information about the usual number of in-home visits per patient over a set period. By doing that, we will try to help with putting the model together so you can ask, for someone who is a cardiology patient, how frequently will they need a primary care intervention annually, or an urgent care intervention annually, or maybe an ambulance transport annually. What share of them will ultimately be handled instead of just watched. So we are right in the thick of this; right now we have a reasonable number of patients enrolled. So at that June gathering, we plan to kind of bring it all together and provide as much detail as we can to help you with building a model, which reflects more than $200 million in value.
Norman Rosenberg
executiveSarah, we're going to examine this from a unit economic perspective as well. So it's not just what Anthony mentioned regarding the estimated lifetime value or annual value of a patient, but additionally on a per-interaction basis. What do the unit economics look like for that sort of thing, and also how do they stack up against the unit economics we've observed in the market that aren't comparable to ours.
Sarah James
analystExcellent. And for my final question, if you don't mind, regarding the Dollar General joint venture — could you share any updates about how those sites are building toward the traffic levels you anticipated, or that Dollar General had been hoping for? Sure.
Lee Bienstock
executiveSarah, this is Lee. So the traffic keeps growing — the traffic keeps growing, and that's something we're thrilled about. I certainly believe we're focused on fine-tuning our marketing approach and getting our promotional blend right; and beyond that, as Anthony said, I think, during the previous call, we're also exploring additional public private partnership possibilities. So you'll see in our release, we mentioned a bit about how a number of the Dollar General sites will function as public health population health sites where underserved populations can also obtain services. So we think those possibilities combined will deliver greater access for people. Dollar General sites make an excellent setting for that access, and we'll keep seeking ways to grow there too.
Anthony Capone
executiveAlso, I should point out that the pilot we're running involves Dollar General, yet it's additionally backed by money from Tennessee's state government. As a result, we're already demonstrating what I mentioned during the previous earnings call — attempting to unite the municipal side with the private side, a public and private partnership, in order to address this genuine health care requirement, which lets go have greater protection for its downside margin; that was the obstacle I brought up when I noted that, clearly, everyone expects us to expand this quickly. I believe it has been a fairly significant success. However, DocGo does not operate fee-for; therefore we don't assume risk on fee-for-service medicine. Consequently, we required a structure that would permit us to safeguard our downside margin. And now that we possess that through the Dollar General pilot, the primary objective at present, or the current stage of Dollar General, is to validate the relationship, figure out whether we can grow this model in which a public-private partnership exists that has strong demand and provides DocGo downside margin protection. That's the point we've reached now.
Analyst
analystThe growth is truly thrilling. It made me really happy to see the activation involving the <<inaudible>>. Could you shed some light on that bullet point of yours about the 911 telemedicine initiative alongside FDNY?
Norman Rosenberg
executiveSure. That 911 initiative we run alongside FDNY's telemedicine effort essentially — it moves into what we refer to as pre-hospital work. This pre-hospital work aims to cut down on the volume of needless visits that otherwise have to be taken to a hospital. So an RFP went out across all of New York City, with plenty of parties placing bids on it; and it has been — this is something that will genuinely benefit the community. So picture DocGo being able to respond, working in partnership with FDNY through our mobile health providers, all under some oversight from a hospital-based telehealth system. That sort of brings together the municipality, the health system, and then DocGo serves as the private provider, all in an effort to lower the number of ER admissions.
Analyst
analystIs that true for every one of the < >?
Norman Rosenberg
executiveYeah, that's right — it covers the whole city, the size immunity, and don't hold me to this since these stats aren't my area of expertise, but FDNY handles millions of transports annually.
Lee Bienstock
executiveRight. What we're aiming to do is assist with sorting through and handling those incoming calls, confirming whether it's truly an emergency situation and whether the person genuinely requires a visit to the ED. And when that's not the case, we then help arrange services for them beyond the ED.
Analyst
analystSo that might represent a significant increase for the transportation segment, at minimum on top of the telemedicine offerings where you actually have real individuals participating on this call.
Anthony Capone
executiveOn the transportation front, I'm not sure, since should they require transport, FDNY would probably be the party handling it; this is genuinely a mobile health chance, though a fairly large one.
Analyst
analystAll right, that makes sense. So maybe I could direct something to Lee. With every one of those RFPs, plus the expansion you've seen in them — and you had a sizable quantity entering that stage — my guess is a fair number are approaching some sort of conclusion. Could it be — is it — reasonable to think there might be something like a bulge, so to speak, in awards, or at minimum some resolution, over the coming several weeks as we move toward the close of this quarter?
Lee Bienstock
executiveYeah. The team definitely can't wait to get responses. On many of these opportunities, I can share that with you. Without question. And responses have already come in on several of them. Typically, the way this process unfolds is that we receive something known as an intent to award; that's the point where the process reaches its conclusion with them contacting us and letting us know if we're the intended awardee, after which we move into the contracting stage. So in certain instances, we've gotten word back on intent to award for strategic reasons, though we don't publicize each individual contract we secure, given competitive considerations. Not every contract we win gets announced. Even so, we have received notification on a few of them, and we're eager to get that word on the rest. And when they reach the point of that contract being completed — not merely an intent to award, but an actual contract in hand — chances are you'll keep hearing more and more regarding those.
Anthony Capone
executiveAlso, to give you a bit more on Jeff, we actually secured a sizable population health agreement — that Tele contract you brought up — plus a big employee health deal out on the West Coast, along with quite a few notable federal government contracts, and plenty of others besides. So responses have come in. It's just that — sometimes we believe we're able to make an announcement without damaging the contract itself or, you know, our strategic IP, so — but a good number have come back to us; and our win rate has stayed pretty steady.
Analyst
analystQuestion from an unidentified analyst: So, then, on top of those 50,000 RPM and CCM patients you believe you'd be handling by the close of this year versus Fresenius and the cardiac side, these wins would come on top of all of it. So it seems like 2024 might bring a pretty major jump in growth compared with where we stand now.
Anthony Capone
executiveCorrect. Neither the ones I just listed nor the ones we've already won appear in any guidance.
Operator
operatorThat brings the question-and-answer portion to a close. Today's teleconference now ends here. At this point, feel free to hang up your lines, and we appreciate your joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.